Document is current

Article History

Received: 24 April 2025

Accepted: 22 May 2025

First Online: 25 June 2025

Declarations

:

: Joachim Nadstawek and Yvonne Wagner received consulting fees from the sponsor Cannamedical Pharma GmbH for scientific and medical consultancy work as advisors and speakers. Ines Samel, Kristina Probst, Lukas Schollenberger and Christian Ruckes have nothing to disclose. Yvonne Wagner is now working as a freelance medical science business consultant at Acantha Lifescience. Ines Samel is currently affiliated with Hormosan Pharma GmbH and Kristina Probst is currently affiliated with AstraZeneca GmbH.

: The study adhered to the principles of the Declaration of Helsinki of 1964 and its later amendments, the German Medicinal Products Act, the professional code of conduct for physicians, and the GDPR in their respective valid versions. In compliance with the German Medicinal Products Act, the study was notified to the Federal Institute for Drugs and Medical Devices, the National Association of Statutory Health Insurance Physicians, the National Association of Statutory Health Insurance Funds, and the Association of Private Health Insurers. Ethical approval was obtained from the coordinating Ethics Committee at the Medical Association of North Rhine (Application number 2021414) and the local ethics committees involved (list of ethics committees in the supplementary material). The study was registered with the German Clinical Trials Registry (DRKS00026906). All patients gave written informed consent before participating.